Literature DB >> 6590091

Sequential karyotypic evolutions and bone marrow aplasia preceding acute myelomonocytic transformation from myelodysplastic syndrome.

M Tomonaga, Y Tomonaga, M Kusano, M Ichimaru.   

Abstract

Serial haematopathological and cytogenetic studies disclosed three distinct clinical phase in a case of refractory anaemia (RA), a subtype of myelodysplastic syndrome (MDS; FAB group, 1982): first, chronic MDS phase (1 year 10 months) with karyotypic abnormality (45, XY, --7) (Clone I); second, hypo-aplastic phase concurrent with first clonal evolution (45, XY, --7, 12p--) (Clone II); third, acute myelomonocytic leukaemia phase (6 months) with second clonal evolution (45, XY, --7,t (1q --; Bq+), Bq --, 12p --) (Clone III). In the second phase the bone marrow became almost aplastic as Clone II expanded progressively, indicating simultaneous occurrence in Clone II stem cells of growth advantage for self-renewal function over Clone I and normal stem cells, and arrest of differentiation. These observations support the hypothesis that leukaemic change in MDS, at least in RA, occurs by stepwise clonal evolution(s), not by progressive arrest of differentiation in original MDS clone.

Entities:  

Mesh:

Year:  1984        PMID: 6590091     DOI: 10.1111/j.1365-2141.1984.tb06058.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  5 in total

1.  Hypocellular myelodysplastic syndromes: clinical and biological significance.

Authors:  Dragomir Marisavljevic; Vesna Cemerikic; Zoran Rolovic; Darinka Boskovic; Milica Colovic
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

Review 2.  Myelodysplastic syndromes: their history, evolution and relation to acute myeloid leukaemia.

Authors:  D M Layton; G J Mufti
Journal:  Blut       Date:  1986-12

3.  Hypoplastic myelodysplastic syndrome: incidence, morphology, cytogenetics, and prognosis.

Authors:  H Maschek; V Kaloutsi; M Rodriguez-Kaiser; M Werner; H Choritz; K Mainzer; M Dietzfelbinger; A Georgii
Journal:  Ann Hematol       Date:  1993-03       Impact factor: 3.673

Review 4.  Myelodysplastic syndromes: pathogenesis, functional abnormalities, and clinical implications.

Authors:  A Jacobs
Journal:  J Clin Pathol       Date:  1985-11       Impact factor: 3.411

Review 5.  Human preleukaemia: do we have a model?

Authors:  A Jacobs
Journal:  Br J Cancer       Date:  1987-01       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.